Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.51 |
| ▸ | IGF1R | P08069 | 3/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.40 |
| ▸ | TTK | P33981 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24327067 | 0.91 | EGFR (0.51) | EGFRALKIGF1RPTK2INSR | |
| SCHEMBL26778475 | 0.87 | ALK (0.56) | EGFRALKIGF1RPTK2INSR | |
| SCHEMBL24327079 | 0.86 | ALK (0.54) | EGFRALKIGF1RPTK2INSR | |
| SCHEMBL24327043 | 0.86 | EGFR (0.61) | EGFRALKIGF1RPTK2INSR | |
| SCHEMBL29015698 | 0.86 | EGFR (0.53) | EGFRALKIGF1RPTK2INSR | |
| SCHEMBL24327565 | 0.86 | EGFR (0.61) | EGFRALKIGF1RPTK2MAP4K1 | |
| SCHEMBL24327573 | 0.85 | ALK (0.53) | EGFRALKIGF1RPTK2INSR | |
| SCHEMBL24327674 | 0.85 | PTK2 (0.57) | EGFRALKIGF1RPTK2INSR | |
| SCHEMBL24327561 | 0.85 | EGFR (0.72) | EGFRALKIGF1RPTK2MAP4K1 | |
| SCHEMBL26778478 | 0.85 | ALK (0.53) | EGFRALKIGF1RPTK2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 13/4885IGF1R 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.